Insulin aspart, recombinant Subcutaneous and Ruxolitinib Phosphate
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Ruxolitinib Phosphate and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: ruxolitinib
Brand name: Jakafi
Synonyms: Ruxolitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Ruzurgi
- Insulin aspart, recombinant Subcutaneous-Ryanodex
- Insulin aspart, recombinant Subcutaneous-Rybelsus
- Insulin aspart, recombinant Subcutaneous-Rybix ODT
- Insulin aspart, recombinant Subcutaneous-RyClora
- Insulin aspart, recombinant Subcutaneous-Rydapt
- Ruxolitinib Phosphate-Insulin degludec
- Ruxolitinib Phosphate-Insulin Degludec (U-100) Prefilled Pens
- Ruxolitinib Phosphate-Insulin Degludec (U-100) Vials
- Ruxolitinib Phosphate-Insulin Degludec (U-200) Prefilled Pens
- Ruxolitinib Phosphate-Insulin degludec and liraglutide
- Ruxolitinib Phosphate-Insulin degludec and liraglutide Subcutaneous